Industry Welcomes UK-EU Northern Ireland Deal
BGMA Says Agreement Provides Certainty For Manufacturers And Patients
A landmark agreement struck between the UK and EU covering medicines supply to Northern Ireland has been welcomed by the UK generics industry as offering certainty to companies operating in the sector as well as patients.
You may also be interested in...
Pressure Grows To Solve Northern Ireland Supply Issues
As political tensions between the UK and EU mount over the Northern Ireland Protocol instigated as part of the pair’s Brexit agreement, the off-patent industry is growing increasingly concerned that regulatory uncertainty will put supply at risk.
Action Needed To Prevent Post-Brexit Catastrophe In Northern Ireland
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”